XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: larotaxel (XRP9881)|DRUG: trastuzumab
Sponsor: Sanofi